Tucatinib - Array BioPharma/Cascadian Therapeutics

Drug Profile

Tucatinib - Array BioPharma/Cascadian Therapeutics

Alternative Names: ARRY-380; Irbinitinib; ONT-380

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Array BioPharma
  • Developer Array BioPharma; Cascadian Therapeutics; Dana-Farber Cancer Institute
  • Class 2 ring heterocyclic compounds; Antineoplastics; Diamines; Furans; Pyridines; Quinazolinones; Small molecules; Triazoles
  • Mechanism of Action ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Colorectal cancer; Breast cancer; Brain metastases
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Colorectal cancer
  • No development reported Solid tumours

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Breast-cancer(Combination therapy, Metastatic disease) in USA (PO, Capsule)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Breast-cancer(Metastatic disease) in Canada (PO, Capsule)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Breast-cancer(Metastatic disease) in USA (PO, Capsule)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top